BioAtla Inc (NASDAQ: BCAB) on Tuesday, plunged -4.06% from the previous trading day, before settling in for the closing price of $0.41. Within the past 52 weeks, BCAB’s price has moved between $0.24 and $2.53.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -10.97% over the last five years. The company achieved an average annual earnings per share of 19.44%. With a float of $44.43 million, this company’s outstanding shares have now reached $58.40 million.
The firm has a total of 76 workers. Let’s measure their productivity. In terms of profitability, gross margin is 97.92%, operating margin of -610.0%, and the pretax margin is -562.51%.
BioAtla Inc (BCAB) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of BioAtla Inc is 23.95%, while institutional ownership is 18.51%.
BioAtla Inc (BCAB) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 19.44% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 8.86% during the next five years compared to -10.97% drop over the previous five years of trading.
BioAtla Inc (NASDAQ: BCAB) Trading Performance Indicators
BioAtla Inc (BCAB) is currently performing well based on its current performance indicators. A quick ratio of 2.35 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.10.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.22, a number that is poised to hit -0.29 in the next quarter and is forecasted to reach -1.11 in one year’s time.
Technical Analysis of BioAtla Inc (BCAB)
Analysing the last 5-days average volume posted by the [BioAtla Inc, BCAB], we can find that recorded value of 0.6 million was lower than the volume posted last year of 0.73 million. As of the previous 9 days, the stock’s Stochastic %D was 12.69%.
During the past 100 days, BioAtla Inc’s (BCAB) raw stochastic average was set at 46.25%, which indicates a significant increase from 7.94% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 69.03% in the past 14 days, which was lower than the 101.27% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.4230, while its 200-day Moving Average is $0.9384. Now, the first resistance to watch is $0.4133. This is followed by the second major resistance level at $0.4316. The third major resistance level sits at $0.4419. If the price goes on to break the first support level at $0.3847, it is likely to go to the next support level at $0.3744. Now, if the price goes above the second support level, the third support stands at $0.3561.
BioAtla Inc (NASDAQ: BCAB) Key Stats
Market capitalization of the company is 23.07 million based on 58,418K outstanding shares. Right now, sales total 11,000 K and income totals -69,780 K. The company made 0 K in profit during its latest quarter, and -14,880 K in sales during its previous quarter.
